

BioThrax[®] (Anthrax) Vaccine in Pregnancy Registry

INFORMATION PAPER: When Pregnancy Is Discovered After Anthrax Vaccination

1. Purpose. This paper provides information for women who discover they are pregnant after receiving BioThrax[®] (anthrax) vaccination.

2. Current Recommendations on Vaccination and Pregnancy

DoD policy exempts pregnant military women from receiving the anthrax vaccine until after the conclusion of pregnancy. However, as it can be difficult to predict conception or diagnose early pregnancy, some women may inadvertently receive anthrax vaccine before pregnancy is recognized.

3. Receipt of the Vaccine during Pregnancy

In a study published in 2008 of more than 115,000 infants born to military women, of whom 3000 were born to women who were inadvertently vaccinated against anthrax in early pregnancy, birth defects were slightly more prevalent among first trimester-exposed infants, but the association was neither strong nor consistently statistically significant. Despite using an extensive database, the study had several limitations including the inability to control for several well-recognized environmental factors that can impact the development of birth defects such as the use of tobacco and alcohol during pregnancy.

After reviewing data from previous studies, and a review of the above referenced study and discussions with the study authors, the Advisory Committee on Immunization Practices (ACIP) concluded that the anthrax vaccine is safe to administer during pregnancy but recommended that pregnant women postpone vaccination unless exposure to anthrax poses an immediate risk for disease.

4. Changes in Vaccine Dose and Route and Surveillance Requirements

In December 2008, Emergent BioSolutions received FDA approval to supplement the biologics license for BioThrax[®] to reflect a change in the vaccination schedule and route of administration. Current immunization with BioThrax[®] consists of a series of five 0.5 mL intramuscular doses administered at 0 and 4 weeks, and 6, 12 and 18 months. Yearly booster injections of 0.5 mL intramuscularly are recommended for those who remain at risk. Previously the vaccine was given as a subcutaneous injection with an additional dose at 2 weeks, and yearly boosters as described for the current schedule. At the time of the 2008 FDA approval, it was determined that BioThrax[®] would remain at Pregnancy Category "D". As acknowledged in the approval, Emergent BioSolutions committed to the development of a Pregnancy Exposure Registry for BioThrax[®] to prospectively collect data on spontaneously-reported exposures to BioThrax[®] during pregnancy with the intent to address elements found in the FDA Guidance for pregnancy registries.

5. BioThrax[®] Anthrax Vaccine in Pregnancy Registry

The Department of Defense, with funding from the vaccine manufacturer, Emergent BioSolutions, has developed the BioThrax[®] (Anthrax) Vaccine in Pregnancy Registry (Registry) to track pregnancies inadvertently exposed to anthrax vaccine. The purpose of the Registry is to assess and estimate the rate of serious adverse maternal and pregnancy outcomes among women exposed to BioThrax[®] during pregnancy, and infant health outcomes among infants born to these women. Active duty military women who receive the anthrax vaccine while pregnant are eligible to join the Registry.

6. Resources for Additional Information

The BioThrax[®] (Anthrax) Vaccine in Pregnancy Registry was established to collect important confidential information from women who received anthrax vaccine in pregnancy. Professionals from the Registry can answer many questions from participants and their healthcare providers. The Registry may be contacted at:

BioThrax[®] (Anthrax) Vaccine in Pregnancy Registry

BioThrax[®] (Anthrax) Vaccine in Pregnancy Registry
c/o DoD Birth and Infant Health Registry,
Naval Health Research Center, Dept. 164, 140 Sylvester Rd., San Diego, CA 92106
Phone: 619-553-9255 (DSN 553)
Fax: 619-767-4806
Email: NHRC-BirthRegistry@med.navy.mil

Additional resources include:

Vaccine Healthcare Centers Network
DoD Vaccine Clinical Call Center
Phone: 866-210-6469

Military Vaccine (MILVAX) Agency
Falls Church, VA
Phone: 877-GET-VACC (877-438-8222) or 703-681-4245 (DSN 761)

References

Wright JG, Quinn CP, Shadomy S, Messonnier N; Centers for Disease Control and Prevention (CDC). Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep. 2010 Jul 23;59(RR-6):1-30.

Ryan MAK, Smith TC, Sevick C, Honner WK, Loach RA, Moore CA, Erickson DJ. Birth defects among infants born to women who received anthrax vaccine in pregnancy. AJE 2008;168(4):434-42.

CDC. Advisory Committee on Immunization Practices (ACIP) meeting minutes archive. Available at <http://www.cdc.gov/vaccines/recs/acip/downloads/min-archive/min-oct08.pdf>. Accessed June 21, 2012.

Food and Drug Administration. December 11, 2008 Approval Letter to Emergent BioDefense Operations Lansing Inc., regarding Anthrax Vaccine Absorbed (BioThrax).

Food and Drug Administration Guidance for Industry Establishing Pregnancy Exposure Registries. Last updated August 2002. Available at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071639.pdf>

This document was last updated 26 June 2012
A. S. Conlin, DO, MPH for the BioThrax[®] (Anthrax) Vaccine in Pregnancy Registry team.